10.15  -0.08 (-0.78%)		02-02 16:00
Open: 10.19 High: 10.1901 Volume: 44,124		Pre. Close: 10.23 Low: 10.14 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	11.98	1-year :	12.07
Resists	First :	10.25	Second :	10.34
Pivot price	10.18
Supports	First :	10.13	Second :	8.42
MAs	MA(5) :	10.14	MA(20) :	10.18
	MA(100) :	10.04	MA(250) :	9.91
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	5.5	D(3) :	5.4
RSI	RSI(14): 47.7
52-week	High :	10.4	Low :	8.3

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ BIOT ] has closed above bottom band by 31.3%. Bollinger Bands are 163.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 24 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	10.17 - 10.22	10.22 - 10.26
Low:	10.01 - 10.08	10.08 - 10.13
Close:	10.05 - 10.16	10.16 - 10.24

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Wed, 13 Mar 2024
Billionaire Mark Cuban rolls out more national AI boot camps, including in St. Louis - The Business Journals

Thu, 29 Feb 2024
7 Best Biotech ETFs to Buy Now | Investing | U.S. News - U.S News & World Report Money

Tue, 09 Jan 2024
JPM24's Medtech Tidbits: Acquisitions, approvals, analysis and more - Fierce Biotech

Fri, 29 Dec 2023
Fierce Biotech Layoff Tracker 2023: Reneo reduces workforce by 70%; Oxurion cuts staff down to 10 - Fierce Biotech

Tue, 26 Dec 2023
AstraZeneca to Buy Cancer Drug Developer for Up to $1.2 Billion - Bloomberg

Thu, 09 Nov 2023
Adaptive Biotech hires Goldman to explore 'strategic alternatives' - GeekWire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Financial Services
Industry: Shell Companies
Shares Out	23 (M)
Shares Float	19 (M)
Held by Insiders	0 (%)
Held by Institutions	116.1 (%)
Shares Short	9 (K)
Shares Short P.Month	1 (K)

EPS	0.25
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.47
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-57.1 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	39.03
PEG Ratio	0
Price to Book value	-22.07
Price to Sales	0
Price to Cash Flow	-335.07

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.